MetaCap

Lisata Therapeutics Inc. (LSTA)

NASDAQ: LSTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.8989-0.0111 (-1.22%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LSTA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$647.45K
EPS (TTM)
-$28.20
52-week range
0.85 – 76.05
Day range
0.85 – 0.90
Volume / Avg
139.26K / 13.46K
Beta
—

52-week range

$0.85$76.05

LSTA stock today

Shares of Lisata Therapeutics (LSTA) finished lower on Nov 20 at $0.8989, a drop of 1.22% or $0.0111 per share, versus the S&P 500's 3.70% decline. Volume was 10.3x the average at 139.26K shares, a sign of unusually heavy trading. At this level, LSTA sits near the bottom of its 52-week range of $0.85 to $76.05: 98.8% below the high and 5.8% above the low.

LSTA is down 51.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.1%. Lisata Therapeutics has posted a net loss over the last twelve months (EPS of -$28.20), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lisata Therapeutics

Company profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.
Headquarters
Basking Ridge, NJ
Employees
21
Website
lisata.com

Financial highlights

Full financials

In fiscal 2024, Lisata Therapeutics generated $170,000 in revenue, down 83.0% from fiscal 2024, its first annual decline since 2011. Lisata Therapeutics reported a net loss of $16.6 million, compared with a loss of $20.0 million a year earlier. Operating margin was -10711.2%.

Lisata Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2024FY 2024FY 2023FY 2022FY 2021
Revenue$170.00K$1.00M$0$0—
Growth-83.00%————
Net income$-16.59M$-19.98M$-20.84M$-54.23M$-27.47M
EPS (diluted)$-1.91$-2.40$-2.58$-10.47$-7.45

Analyst forecast

Forecast

Consensus (2 analysts)

none

  • Strong buy 0
  • Buy 0
  • Hold 2
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.73 vs —

LSTA news

All LSTA news

Lisata Therapeutics peers

Health Care sector
LSTA peer companies
CompanyPrice% ChgMarket capCompare
OGENOragenics Inc.0.157-8.72%$708.38Kvs LSTA
SPRCSciSparc Ltd.0.1955-34.83%$481.60Kvs LSTA
CDTCDT Equity Inc.0.23-13.89%$437.03Kvs LSTA
MTNBMatinas Biopharma Holdings Inc.0.7999-1.26%$890.71Kvs LSTA
BDRXBiodexa Pharmaceuticals plc American Depositary Shs1.88-3.85%$982.95Kvs LSTA
GOVXGeoVax Labs Inc.1.81-5.24%$985.46Kvs LSTA
SXTCChina SXT Pharmaceuticals Inc.2.65+2.12%$273.95Kvs LSTA
ARTLArtelo Biosciences Inc.1.39-4.14%$1.30Mvs LSTA

Indexes, lists and sector

Lisata Therapeutics stock FAQ

What is Lisata Therapeutics's stock price today?

LSTA last traded at $0.8989 as of Nov 20, 4:00 PM EST, down 1.22% on the day. Prices are delayed at least 15 minutes.

Does Lisata Therapeutics pay a dividend?

No. Lisata Therapeutics does not currently pay a regular cash dividend.

Who is Lisata Therapeutics's CEO?

Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. is the chief executive officer of Lisata Therapeutics Inc., which has about 21 employees.

Has LSTA ever split its stock?

Yes. The most recent LSTA stock split was a 1-for-15 split on Nov 23, 2026, one of 6 splits on record.

What is the LSTA 52-week high?

The 52-week high for LSTA is $76.05 and the 52-week low is $0.85. The stock is currently 98.8% below its high.

Compare LSTA